Highlights the diagnostic challenges of rare low-grade extraskeletal osteosarcomas and the utility of molecular analysis of MDM2 and CDK4 oncogenes.
Answers are grounded in this paper and cite their sources.
Alerts to dismal prognosis in advanced extraskeletal osteosarcoma despite chemotherapy; leaves open whether MDM2/CDK4 testing refines management.
BACKGROUND: Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare. CASE PRESENTATION: We present the first case of low-grade ESOS of the chest wall, which occurred in a 30-year-old man. Because of initial misdiagnosis and patient's refusal of surgery, the diagnosis was done after a 4-year history of a slowly growing mass in soft tissues, leading to a huge (30-cm diameter) calcified mass locally extended over the left chest wall. Final diagnosis was helped by molecular analysis of MDM2 and CDK4 oncogenes. Unfortunately, at this time, no surgical treatment was possible due to loco-regional extension, and despite chemotherapy, the patient died one year after diagnosis, five years after the first symptoms. CONCLUSION: We describe the clinical, radiological and bio-pathological features of this unique case, and review the literature concerning low-grade ESOS. Our case highlights the diagnostic difficulties for such very rare tumours and the interest of molecular analysis in ambiguous cases.
No takes yet. Share an insight, caveat, or question.
Sabatier et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: